DURECT Co. (NASDAQ:DRRX) Expected to Post Earnings of -$0.05 Per Share

Equities analysts forecast that DURECT Co. (NASDAQ:DRRXGet Rating) will post ($0.05) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for DURECT’s earnings. DURECT also reported earnings of ($0.05) per share in the same quarter last year. The company is expected to issue its next quarterly earnings results after the market closes on Monday, January 1st.

On average, analysts expect that DURECT will report full-year earnings of ($0.19) per share for the current year, with EPS estimates ranging from ($0.20) to ($0.18). For the next fiscal year, analysts expect that the business will report earnings of ($0.10) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow DURECT.

DURECT (NASDAQ:DRRXGet Rating) last issued its quarterly earnings results on Monday, March 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.02. The firm had revenue of $7.30 million during the quarter, compared to analyst estimates of $2.40 million. DURECT had a negative return on equity of 52.37% and a negative net margin of 259.46%. During the same quarter in the previous year, the company posted ($0.04) earnings per share.

DRRX has been the topic of a number of research analyst reports. StockNews.com began coverage on DURECT in a report on Friday. They set a “hold” rating on the stock. Zacks Investment Research downgraded DURECT from a “buy” rating to a “hold” rating in a report on Wednesday, February 23rd.

Shares of NASDAQ:DRRX opened at $0.45 on Friday. DURECT has a 1 year low of $0.40 and a 1 year high of $1.93. The company has a debt-to-equity ratio of 0.36, a quick ratio of 7.94 and a current ratio of 8.13. The stock’s 50-day moving average is $0.57 and its 200 day moving average is $0.82.

In other news, Director Judith J. Robertson acquired 200,000 shares of DURECT stock in a transaction that occurred on Monday, March 14th. The stock was bought at an average price of $0.59 per share, for a total transaction of $118,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.60% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC purchased a new stake in shares of DURECT during the third quarter worth about $29,000. Kovack Advisors Inc. bought a new position in DURECT during the fourth quarter valued at approximately $25,000. Teacher Retirement System of Texas boosted its stake in DURECT by 35.6% during the third quarter. Teacher Retirement System of Texas now owns 35,579 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 9,344 shares during the last quarter. Ancora Advisors LLC bought a new position in DURECT during the third quarter valued at approximately $50,000. Finally, BNP Paribas Arbitrage SA boosted its stake in DURECT by 330.0% during the third quarter. BNP Paribas Arbitrage SA now owns 43,064 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 33,050 shares during the last quarter. Institutional investors and hedge funds own 50.60% of the company’s stock.

DURECT Company Profile (Get Rating)

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

See Also

Get a free copy of the Zacks research report on DURECT (DRRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.